ArticleIndian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine2020
Mucormycosis in a Tertiary Care Center in South India: A 4-Year Experience.
Article in Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 47 citations in OpenAlex.
- View of mucormycosis during the era of COVID-19 infection: A cross-sectional study.Journal of family medicine and primary care · 2023Article
- Clinicoradiological Profile of COVID-19-Associated Rhino-Orbital Cerebral Mucormycosis with a Focus on Computed Tomography: A Clinical Case Series and Review.The American journal of tropical medicine and hygiene · 2023Observational
- Mucormycosis and Its Upsurge During COVID-19 Epidemic: An Updated Review.Current microbiology · 2023Review
- Traumatic mucormycosis caused by Apophysomyces species - A case series.Journal of orthopaedics · 2023Article
- The Fragile Patient: Considerations in the Management of Invasive Mould Infections (IMIs) in India.Cureus · 2023Review
- Rise of mucormycosis during the COVID-19 pandemic and the challenges faced.Current medical mycology · 2023Review
- Mucormycosis and diabetes in the times of COVID-19: A Mumbai-based observational study.Journal of family medicine and primary care · 2022Article
- Role of COVID 19 Inflammatory Markers in Rhino-Orbito-Cerebral Mucormycosis: A Case Study in Predisposed Patients at a Designated Nodal Centre.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2022Article
- Review
- COVID-19, Mucormycosis and Cancer: The Triple Threat-Hypothesis or Reality?Journal of personalized medicine · 2022Review
- Mucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic.Folia microbiologica · 2022Review
- Mucormycosis in COVID-19 pandemic: Risk factors and linkages.Current research in microbial sciences · 2021Article
- Epidemiology of Mucormycosis in India.Microorganisms · 2021Review
- Mucormycosis: Cytomorphological Spectrum in Fine-Needle Aspiration Cytology.Journal of cytologyArticle
- Temporal and Geographic Variations and Patient Factors in Acute Invasive Fungal Sinusitis: A Scoping Review.Therapeutic advances in allergy and rhinologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMucormycosis is an emerging fungal infection in both developed and developing countries with different target population. Unusual isolates and unusual clinical presentations have been reported from India in recent times.
objectivesThe present study was done to know the epidemiology, risk factors, diagnostic modalities, and treatment outcome of mucormycosis patients in our hospital. MATERIALS AND
methodsThe study was carried out over a period of 4 years from October 2015 to October 2019. This is a retrospective observational chart review of patients diagnosed with proven and probable mucormycosis. Information on demography, clinical features, risk factors, laboratory and radiological findings, treatment (including medical and surgical treatment), and outcome was extracted from the records. Primary outcome at 42 days was determined.
resultsThirty-eight patients were diagnosed with mucormycosis based on microbiological and/or histopathological examination (HPE) of the clinical samples. Most commonly affected age-group was between 41 years and 60 years. More number of cases were reported during the months of post rainy season (September to December). A large number of patients (77%) presented with uncontrolled diabetes mellitus. Rhino-orbito-cerebral mucormycosis was the most common presentation followed by cutaneous infection. Antifungal treatment was started in around 80% of the cases. Twenty patients were managed by combined medical and surgical intervention. Eight patients died while the outcome of nine was unknown, as they left the hospital against medical advice and could not be followed up.
conclusionMucormycosis, an insidious killer, should be an important differential diagnosis in progressive soft tissue infections and deep organ infection. HOW TO CITE THIS ARTICLE: Priya P, Ganesan V, Rajendran T, Geni VG. Mucormycosis in a Tertiary Care Center in South India: A 4-Year Experience. Indian J Crit Care Med 2020;24(3):168-171.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.